<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437981</url>
  </required_header>
  <id_info>
    <org_study_id>PrEP-30 demonstration project</org_study_id>
    <nct_id>NCT02437981</nct_id>
  </id_info>
  <brief_title>Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic</brief_title>
  <acronym>PrEP-30</acronym>
  <official_title>Thai Red Cross AIDS Research Centre (TRC-ARC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thai Red Cross AIDS Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PrEP-30 is a demonstration project to assess the feasibility of providing oral PrEP to MSM&#xD;
      and other individuals at-risk for HIV in Bangkok, Thailand as a service that is funded&#xD;
      entirely through user fees. Tenofovir disoproxil fumarate/emtricitabine PrEP is provided part&#xD;
      of a combined HIV prevention program that includes risk-reduction counseling, regular HIV&#xD;
      testing, and the provision of condoms and lubricants. PrEP-30 is implemented at the Thai Red&#xD;
      Cross AIDS Research Centre, at the site of the largest HIV counseling and testing center in&#xD;
      Thailand.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measures:</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the uptake of fee-based oral PrEP by MSM and other at-risk individuals who present for HIV testing or other services.&#xD;
Assess the acceptability, tolerance and safety of oral PrEP.&#xD;
Assess patient satisfaction with oral PrEP delivered through a fee-based system in an HIV testing center.&#xD;
Assess the effectiveness of oral PrEP in a fee-based model.&#xD;
Assess the cost-effectiveness of oral PreP delivered in a fee-based system.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>HIV Prevention</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP</intervention_name>
    <description>Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MSM and other individuals at risk for HIV infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. HIV test negative&#xD;
&#xD;
          3. Creatinine clearance &gt; 60 ml/min&#xD;
&#xD;
          4. No contraindication or allergy to PrEP medications (TDF/FTC)&#xD;
&#xD;
          5. At least one risk factor for HIV infection within the previous 6 months:&#xD;
&#xD;
               -  sex partner known to be HIV positive&#xD;
&#xD;
               -  works as commercial sex worker&#xD;
&#xD;
               -  use of PEP for sexual exposure&#xD;
&#xD;
               -  injection drug use&#xD;
&#xD;
               -  any STI (syphilis, gonorrhea, chlamydia)&#xD;
&#xD;
               -  &gt; 5 sex partners&#xD;
&#xD;
               -  inconsistent condom use with high-risk partners, including MSM, IDU&#xD;
&#xD;
                    -  MSM: any insertive or receptive anal sex without condom&#xD;
&#xD;
                    -  Women: any sex without condom with high-risk male partner (MSM, IDU,&#xD;
                       multiple female partners)&#xD;
&#xD;
                    -  Heterosexual men: any sex without condom with high-risk female partner&#xD;
                       (commercial sex worker, IDU, multiple male partners)&#xD;
&#xD;
        Exclusion Criteria: -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <state>Pathumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

